BioLineRx (BLRX) Receivables (2022 - 2025)

BioLineRx has reported Receivables over the past 4 years, most recently at $456000.0 for Q4 2025.

  • Quarterly results put Receivables at $456000.0 for Q4 2025, down 88.47% from a year ago — trailing twelve months through Dec 2025 was $456000.0 (down 88.47% YoY), and the annual figure for FY2025 was $456000.0, down 88.47%.
  • Receivables for Q4 2025 was $456000.0 at BioLineRx, down from $4.0 million in the prior quarter.
  • Over the last five years, Receivables for BLRX hit a ceiling of $4.0 million in Q4 2024 and a floor of $456000.0 in Q4 2025.
  • Median Receivables over the past 4 years was $954500.0 (2022), compared with a mean of $1.6 million.
  • Biggest five-year swings in Receivables: skyrocketed 232.83% in 2024 and later crashed 88.47% in 2025.
  • BioLineRx's Receivables stood at $721000.0 in 2022, then surged by 64.77% to $1.2 million in 2023, then skyrocketed by 232.83% to $4.0 million in 2024, then crashed by 88.47% to $456000.0 in 2025.
  • The last three reported values for Receivables were $456000.0 (Q4 2025), $4.0 million (Q4 2024), and $1.2 million (Q4 2023) per Business Quant data.